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Background: Chronic venous stasis ulcers produce substantial morbidity rates and result in a significant expense to society.
Fortunately, compression stockings (CS) have been found to reduce the rate of recurrence in patients with previous
ulceration. Surprisingly, Medicare and other insurers do not reimburse the expense associated with CS or with patient
education (Ed), which is essential to ensure compliance.
Methods: A Markov decision analysis model was used for analysis of the cost-effectiveness of a strategy of reimbursement
for CS and Ed (prophylaxis) versus one that does not supply these resources in a 55-year-old patient with prior venous
stasis ulceration. The mean time to ulcer recurrence (53 months with CS1Ed; 18.7 months without prophylaxis), the
mean time for ulcer healing (4.6 months), the probabilities of hospitalization (12%) and amputation (0.4%) after the
development of an ulcer, and quality-adjustment factors (0.80 during ulcer treatment) were derived from the literature.
The cost of CS ($300/year) and Ed ($93 for initial evaluation; $58/year; $40/recurrence) and the medical cost of ulcer
treatment (average cost, $1621/recurrence) were calculated from our hospital cost accounting system.
Results: A strategy of CS and Ed was cost saving, with 0.37 quality-adjusted life years and $5904 saved, compared with
a strategy that does not provide these resources. The inclusion of loss of revenue related to absence from work in the
analysis increased cost savings to $17,080 during the patient’s lifetime. With sensitivity analysis, CS and Ed remained
cost-effective (lifetime cost per quality-adjusted life year saved, <$60,000) if amputations and the cost of ulcer treatment
were eliminated or if the cost of prophylaxis was increased to 600% of the base-case. The mean time to recurrence in
patients with CS and Ed needed to be reduced from 53 months to 21.1 months before this strategy was no longer
cost-effective.
Conclusion: Prophylactic CS and Ed in patients with prior venous stasis ulceration are cost saving, even with the most
conservative of assumptions. Insurers should routinely reimburse for these interventions. (J Vasc Surg 10.1067/
mva.2002.121984.)
Lower extremity ulceration associated with venous in-
sufficiency affects approximately 1% of Western society’s
population.1-4 Moreover, approximately 90% of all chronic
wounds are related to venous stasis ulceration.3,5 This
clinical problem imposes a large economic burden on soci-
ety.2,5-7 In addition to the direct cost of treatment of venous
ulceration and its complications, including cellulitis or ampu-
tation, there are also indirect costs associated with time absent
from work, forced early retirement, and loss of functional
independence.6-8 Quality of life may be considerably reduced
in patients with chronic venous insufficiency both during and
subsequent to the development of ulceration.7,9,10
The standard treatment for venous ulceration is leg eleva-
tion, skin care, and compression therapy. After a venous ulcer
has healed, graded compression stockings are worn to control
peripheral edema. Ulcer recurrence is common, particularly in
patients who are noncompliant with compression thera-
py.11-13 Numerous investigators have found that compliance
is dependent on patient access to compression stockings and
appropriate education.11,12,14 Despite this realization, this
country’s largest health insurance program, Medicare, does
not reimburse for either of these costs. Compression stockings
are expensive, particularly for elderly patients on social secu-
rity. A therapy that is initially uncomfortable and needs signif-
icant patient effort is destined to fail without proper patient
education and encouragement.
In this analysis, we evaluate the economic wisdom of a
policy in which compression stockings and education for
patients who have chronic venous insufficiency are not
reimbursed. We designed a decision-analysis model that
incorporates the cost of prophylactic compression stock-
ings and patient education, the cost of treatment of stasis
ulceration and its complications, and the diminution in the
quality of life associated with recurrence of venous stasis
ulceration. The objective of this analysis is to determine the
cost-effectiveness of a prophylactic program that includes
reimbursement for compression stockings and patient ed-
ucation for the treatment of patients with a history of
venous stasis ulceration.
METHODS
Decision analysis model
We developed a state-transition (Markov) model15 that
reflects the possible clinical outcomes and costs in a cohort
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of 55-year-old patients with a history of venous stasis
ulceration (Fig 1). Patients were provided either a prophy-
lactic program that included reimbursement for compres-
sion stockings and patient education with a focus on com-
pliance (CS and Ed) or neither of these resources (no
prophylaxis). Each group then was subdivided into compli-
ant and noncompliant patient groups with respect to ad-
herence to compression therapy. During follow-up exami-
nation, every patient assumed one of several states of
health, including no active ulceration, recurrent ulceration
with or without hospitalization for cellulitis or amputation,
and death. Each of these Markov states is associated with a
utility that indicates the health-related quality of life of that
state and a cost. Transitions between these states could be
made on a 3-month basis, determined by transition prob-
abilities. All utilities and costs associated with the health
states patients assumed during their lifetimes were aggre-
gated with a computerized Markov model (DATA 3.5.4,
Treeage software, Inc, Williamstown, Mass; 1998). Age-
specific annual mortality rates were on the basis of standard
1997 US life tables.16 The main measure of outcome for
each treatment alternative was life expectancy in quality-
adjusted life years (QALYs) and the lifetime treatment
costs.
Cost-effectiveness analyses are on the basis of the
premise that two strategies are compared. If the strategy
evaluated costs more and is less effective than the alternative
(ie, the strategy is dominated by the alternative), then this
strategy is clearly not cost-effective and should not be
adopted. If a strategy costs more but is more effective than
the alternative, then an incremental cost-effectiveness ratio,
defined as the additional cost per QALY gained, can be
determined. The lower the ratio, the more cost-effective an
intervention. If a strategy costs less and is more beneficial
than the alternative (ie, the strategy is dominant over the
alternative), then a cost-effectiveness ratio cannot be deter-
mined. With this circumstance, the strategy is considered to
be cost saving and should clearly be adopted.
In our initial analysis (base-case analysis), our single
best estimates of probabilities, costs, and quality-adjust-
ment factors were used. These variables were systematically
varied through a wide range, and the effect of these varia-
tions on the base-case conclusion was determined (sensitiv-
ity analyses). Because most widely accepted medical inter-
ventions have cost-effectiveness ratios of less than $60,000
(eg, coronary artery bypass grafting for left main disease,
$14,000; chronic hemodialysis, $54,000), we considered
this value to be the threshold for our sensitivity analysis.17
All costs were converted to 1999 US dollars with the
medical care component of the Consumer Price Index for
All Urban Consumers. In accordance with standard princi-
ples of economic analysis, costs and life expectancies were
discounted at 3% per year to reflect the greater value of
current dollars and the patient’s preference towards current
benefits compared with those of the future.18
Probabilities and costs
After a thorough literature search, we assigned transi-
tion probabilities and costs to our model (Table I). We
determined the costs, not the charges or reimbursements,
for the various interventions and complications. Costs were
derived from the cost accounting system at the New York
Presbyterian Hospital (Transition Systems, Inc, Boston,
Mass) and from the literature. Professional fees were de-
rived from the standard Medicare reimbursement for the
appropriate Current Procedural Terminology codes.
Recurrence rates and patient compliance. In two
published studies of compression therapy after venous stasis
ulceration, the authors have defined compliant versus non-
compliant patient groups and assessed the ulcer recurrence
rates in these subgroups by means of actuarial meth-
ods.11,13 We adopted these definitions and used the life-
table data from these studies to derive average recurrence
rates for our compliant and noncompliant subgroups. For
this purpose, we calculated the hazard rates corresponding
to the life-table data and derived the declining exponential
approximation for time to ulcer recurrence. For compliant
and noncompliant patient groups, we determined average
recurrence rates of 1.8%/month and 5.3%/month, respec-
tively, or alternatively an average time to ulcer recurrence of
53 and 18.7 months, respectively. Our model is predicated
on the contention that the provision of stockings and
education is a major determinant of compliance with com-
pression therapy.12 For the base-case analysis, we assumed
that patients with reimbursement for stockings and educa-
tion would be compliant; patients who did not receive these
resources would be noncompliant, as defined in the previ-
ously mentioned studies.11,13 Hence, in the base-case anal-
Fig 1. Simplified Markov decision analysis model. A, Hypotheti-
cal cohort of 55-year-old patients with history of venous stasis
ulceration is provided either with prophylactic compression stock-
ings and education or neither of these resources. Either cohort
then is subdivided in patients compliant or noncompliant with
compression therapy. B, Each subgroup then enters the Markov
process in which patients can move between the indicated health
states on a 3-month basis, according to predefined transition
probabilities. Each state is assigned a quality adjustment factor and
cost. The cohort is followed until all patients have died. CS,
Compression stockings; Ed, patient education.
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ysis, 100% of patients in the intervention arm and 0% of the
patients in the control arm were considered compliant. We
then varied these numbers in sensitivity analysis.
Medical costs related to ulcer treatment. For our
base-case analysis, we assumed that patients with venous
stasis ulceration would first undergo thorough evaluation
by a physician (initial visit, $91) followed by treatment with
Unna’s paste boots (medicopaste, Graham-Field, Hauppa-
gauge, NY).19 A nurse with physician supervision would
change the boot during clinic visits at weekly intervals until
the ulceration healed. The weekly cost of the Unna’s paste
boot was determined as follows: boot and Ace wrap, $11;
other supplies, $5; nursing, $20 (30 minutes, on the basis
of an annual salary of $45,000 and 25% fringe benefits);
clinic overhead, $8; physician evaluation, $18; and total
cost, $62. On the basis of data from four studies, we derived
an average rate of healing for venous stasis ulceration of
22% per month (mean duration of treatment, 4.6
months).11,13,20,21 We assumed that 12% of patients with
venous stasis ulceration would need hospitalization for
cellulitis or other complications,5,21 with an associated cost
of $2400 per event.5 Pooled data from the previous four
studies (533 treated ulcers) indicated a 0.4% probability
that recurrent ulceration would result in amputa-
tion.11,13,20,21 However, because these patients may be
derived from a subset with coexisting peripheral vascular
disease, which may complicate compression therapy, we
excluded the possibility of amputation in sensitivity analy-
sis. For the base-case, the cost of amputation and subse-
quent rehabilitation was estimated at $61,570 for the 1st
year and $39,735 for each year thereafter, on the basis of
the assumption that 29% of amputees need long-term
nursing care.22,23 An annual excess mortality rate of 12%
was ascribed to patients who underwent amputation.24
Costs related to days absent from work. In our
base-case analysis, we included only medical costs. In sen-
sitivity analyses, however, we included the monetary cost to
society related to the days absent from work for patients
undergoing treatment for venous stasis ulceration. The
patient age for the base-case was 55 years at entry into this
study. We assumed that one half of these individuals would
be actively employed until age 65 years and that these
individuals would not return to work until their venous
stasis ulceration had completely healed. The cost to society
related to the time absent from work was determined on the
basis of an average salary of $25,598 per year.25
Cost of prophylaxis. We assumed that a program for
prevention of the recurrence of venous stasis ulceration
would include life-long reimbursement for compression
stockings and an intensive education program conducted
by a nurse clinician. We assumed that patients would be
allotted two pair of compression stockings every 6 months
at a cost of $75 per pair ($300/year). Our education
program consisted of a half hour visit with a nurse clinician
Table I. Key variables of the model: base-case assumptions and ranges tested in sensitivity analysis
Variables and costs Base-case Sensitivity analysis
Age at initial ulceration (y)11,13 55 30-90
Rates/probabilities
Mean time to ulcer recurrence with compliance (months)*11,13 53.0 53.0-18.7
Mean time to ulcer recurrence with noncompliance (months)*11,13 18.7
Compliance in patients with CS and Ed†11-13 100% 0-100%
Compliance in patients without CS and Ed†11-13 0
Mean time for ulcer healing (months)*11,13,20,21 4.6
Incidence rate of hospitalization (per recurrence)5,21 12% 0-24%
Risk of amputation (per recurrence)11,13,20,21 0.4% 0.0-0.4%
Annual excess mortality rate after amputation24 12% 0
Cost of prophylaxis
Compression stockings (per year)‡ $300
Nursing education (per year)‡ $40
3100%-800%Additional education at time of ulcer recurrence‡ $40
Physician evaluation (1st year through subsequent years)§ $93-$18
Costs related to ulcer treatment
Physician reimbursement (initial visit)§ $91
Unna’s paste boot change (per week)‡ $62 30%-200%
Cost per hospitalization for complications5 $2400
Cost per month lost from work25 $0 0-$1050
Cost of amputation (1st year through subsequent years)22 $61,570-$39,735
Quality-adjustment factors
Chronic venous insufficiency without ulceration27 0.96 0.70-0.96
Patient undergoing ulcer treatment7,9,10 0.80 0.70-0.96
Amputation26 0.70
Disutility for hospitalization (days) 5 0
*Mean time is reciprocal of rate entered into model.
†Reflects compliant and non-compliant groups as defined by Erickson et al11 and Mayberry et al.13
‡Cost accounting system at New York Presbyterian Hospital (Transition Systems, Inc, Boston, Mass).
§Medicare reimbursement according to Current Procedural Terminology codes.
CS, Compression stockings; Ed, patient education.
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($20) that coincided with the initial physician visit for
patients entering the program followed by half hour nurs-
ing education visits every 6 months ($40/year). Patients
enrolled in the program of prophylaxis in whom ulceration
developed received 1 hour of nursing education during the
course of treatment.
Quality weights
A quality-adjustment factor is assigned to each state of
health on the basis of the patient’s perception of quality of
life associated with these states. This quality-adjustment
factor may range from 0 (death) to 1 (perfect health). On
the basis of three analyses regarding the impact of lower
extremity ulceration on the quality of life,7,9,10 we applied
a quality-adjustment factor of 0.80 to patients during the
active period of treatment of their venous stasis ulceration.
For major amputation, we used a quality-adjustment factor
of 0.70.26 Hospitalized patients were assigned a disutility of
5 days: paraphrased, 5 days were subtracted from their
overall life expectancy. A quality adjustment factor of 0.96
was assigned to all patients without ulceration to account
for symptoms related to chronic venous insufficiency.27
RESULTS
Base-case analysis
For the hypothetical cohort of 55-year-old patients
with a history of ulceration related to chronic venous stasis,
a program of prophylaxis that included compression stock-
ings and education increased the quality-adjusted life ex-
pectancy by 0.37 QALYs and reduced the lifetime cost by
$5904 (Table II). Thus, a strategy of prophylaxis in these
patients is cost saving compared with a strategy in which
these resources are not provided.
Sensitivity analyses
The robustness of our base-case assumptions was tested
in sensitivity analyses by substituting a wide range of values
for each variable (see Table I). This process allowed deter-
mination of the margin of confidence in support of our
conclusion.
Recurrence rates and patient compliance. Our base-
case conclusion was on the basis of the finding that com-
pression therapy increases the mean time to ulcer recur-
rence from 18.7 in noncompliant patient groups to 53.0
months in compliant patient groups.11,13 For this analysis,
we assumed that patients who received CS and Ed would be
100% compliant and those who did not would be 0%
compliant. We realize, however, that despite economic
incentives and encouragement, some patients will never
consistently wear stockings and others will be compliant
without these incentives. We therefore believed that per-
cent compliance would be an important variable to test in
sensitivity analysis. We found that the compliance rate with
CS and Ed needed to be decreased to 52% before the
prophylactic program was no longer cost saving. It needed
to be decreased to 16% before it was no longer cost-
effective (Fig 2A). A similar margin was found when the
time to ulcer recurrence was evaluated in sensitivity analy-
sis. The mean time to ulcer recurrence in compliant patient
groups had to be reduced to 27.7 months before a program
of prophylaxis was no longer cost saving and to 21.1
months to render CS and Ed cost-ineffective (Fig 2B).
Treatment costs of recurrent ulceration and its
complications. With base-case conditions (mean time for
healing, 4.6 months; hospitalization in 12%), the average
cost for treatment of an ulcer recurrence amounted to
$1621. If this cost was increased any measure (eg, with the
assumption of longer healing times), the prophylactic strat-
egy became more cost saving. If this cost was reduced, the
net gain of prophylaxis diminished. However, even if the
treatment cost of venous stasis ulceration was reduced by
98%, the prophylactic strategy remained cost saving. In the
base-case analysis, we used a probability for amputation of
0.4% per ulcer recurrence. If amputation and its attendant
costs were excluded from this analysis, CS and Ed still
remained a cost-saving strategy (0.26 QALYs and $1437
saved). CS and Ed remained cost-effective (ratio, $19,952/
QALY) if both the cost of ulcer treatment and the proba-
bility of amputation were completely eliminated from the
analysis (Fig 2C). The gain in quality of life resulting from
fewer episodes of ulceration was sufficient to allow a pro-
phylactic strategy to remain cost-effective despite elimina-
tion of the cost of ulcer treatment from the model.
Cost of prophylaxis. The base-case value for the cost
of prophylaxis was $358 per year plus additional costs at the
time of initiation of the program and at each ulcer recur-
rence of $93 and $40, respectively. If these costs were
reduced, a strategy of prophylaxis became more cost saving.
The costs of prophylaxis needed to be increased to 210% of
the base-case cost ($750 1 $195 1 $84, respectively)
before this strategy was no longer cost saving. These costs
needed to be further increased to 600% before prophylaxis
was no longer cost-effective (Fig 2D).
Costs related to days absent from work. The indi-
rect costs to society caused by venous stasis ulcers (which
include the loss of revenue related to time away from work
during ulcer treatment) were not incorporated into our
base-case analysis. In sensitivity analysis, the addition of this
expense increased the lifetime costs to $22,412 and
$39,496 for patients enrolled and not enrolled in the
prophylactic program, respectively. Hence, when indirect
Table II. Base-case results: compression stockings and
patient education versus no prophylaxis prolongs quality-
adjusted life expectancy at reduced lifetime costs (ie,
compression stockings and patient education is a cost-
saving strategy)
QALYs Lifetime costs
No prophylaxis 14.68 $20,492
CS and Ed 15.05 $14,588
CS and Ed versus no prophylaxis 0.37 2$5904
QALY, Quality adjusted life years; CS, compression stockings; Ed, patient
education.
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costs were considered, a strategy to prevent ulcer recur-
rence became extraordinarily cost saving ($17,080 saved
during the lifetime of each patient).
Quality weights. In general, the life expectancy of a
cohort of patients with venous stasis ulceration is not
significantly diminished.28 The decreased survival rate in
the rare patient with amputation plays only a minor role.
However, changes in quality of life in patients with ulcer-
ation did have a significant effect on the quality-adjusted
life expectancy. In our base-case analysis, we assigned a
quality-adjustment factor of 0.80 to patients during the
period of ulcer treatment. This resulted in an increment of
0.37 QALYs provided with the prophylactic strategy. If the
quality adjustment for ulcer treatment was increased to
0.96 (identical to the factor assigned to patients without
ulceration), the incremental quality-adjusted life expect-
ancy was reduced to 0.12 QALYs. The reduction of the
quality-adjustment factor for ulcer treatment increased the
utility of prophylactic treatment (eg, a factor of 0.70 rather
than 0.80) and yielded an incremental life expectancy of
0.48 QALYs. Amputation with its attendant excess mortal-
ity rate and reduced quality of life had a lesser impact on the
quality-adjusted life expectancy. The elimination of the
probability of amputation reduced the incremental life
expectancy to 0.26 QALYs.
Other variables. Varying the cost or frequency of
hospitalization for cellulitis, the patient’s age, the excess
mortality rate after amputation, and the discounting factor
had no substantial effect on the outcome of our base-case
analysis. Increasing a patient’s age decreased the magnitude
of the savings per patient proportional to the decline in life
expectancy. However, even in 90-year-old patients, the
base-case conclusion did not change (CS and Ed saved
$665 and 0.06 QALYs).
Fig 2. Sensitivity analyses. Gain in quality-adjusted life years with compression stockings and patient education versus
no prophylaxis as function of four key variables. Threshold for cost-effective medical interventions was defined as
$60,000/quality-adjusted life year (dashed line); negative cost-effectiveness ratio indicated cost savings. A, Compliance
rate in patients with compression stockings and education needed to be decreased to 52% or 16% of base-case
assumption before prophylactic program was no longer cost saving or cost-effective, respectively. B, Mean time to
recurrence in patients compliant with compression stockings and education (base-case, 53 months) had to be reduced
to 27.7 months or to 21.1 months before program of prophylaxis was no longer cost saving or cost-effective,
respectively (base-case for noncompliance, 18.7 months). C, Declining costs of ulcer treatment showed that compres-
sion stockings and education remained cost-effective, even if amputations were excluded at same time (depicted graph).
If amputations were considered, compression stockings and education remained cost saving until treatment cost of
venous stasis ulceration was reduced by 98% (not depicted). D, Costs of prophylaxis had to be increased to 210% or to
600% of base-case costs before prophylactic program was no longer cost saving or cost-effective, respectively. (X-axis
depicts baseline cost of prophylaxis per patient-year without recurrence. Additional educational costs at initial
presentation or ulcer recurrence were adjusted proportionally.) *Base-case assumption. CS, Compression stockings; Ed,
patient education; QALY, quality-adjusted life year.
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DISCUSSION
Chronic venous stasis is a prevalent disease that pro-
duces substantial disability at high cost to society.5,6 Soci-
etal expense is derived both from the medical costs associ-
ated with treatment and from the economic burden related
to time absent from work. The incidence rate of new cases
of venous stasis ulceration in the United States was pro-
jected in a recent epidemiologic analysis by Heit at al.2
These authors conservatively estimated that each year at
least 20,556 new patients are diagnosed with a venous stasis
ulcer. In the United States, the direct medical costs alone
have been estimated to be between $150 million and $1
billion annually.2,5 Although the medical treatment of
these patients has been fairly well defined, particularly the
use of compression stockings and patient education to
prevent recurrent ulceration, support for these therapies in
terms of economic reimbursement is lacking. Although
many insurers, including Medicare, are more than willing
to pay for the treatment of venous stasis ulcers and their
sequelae, these same organizations are unwilling to reim-
burse for measures designed to prevent ulceration. Because
the value of compression stockings and patient education in
the prevention of recurrent venous stasis ulceration has
been well documented, one must assume that insurers are
concerned that these prophylactic measures are too costly.
In this study, with a formal decision analysis model, we
directly address the issue of cost of a prophylactic strategy
designed to prevent recurrent stasis ulceration.
The utility of a Markov model is its ability to evaluate
not only the immediate costs associated with a disease
process but also the costs that are incurred during the
lifetime of a patient. For the 55-year-old patients with a
history of venous stasis ulceration (average life expectancy,
25 years),16 the yearly cost of the compression stockings
and visits from a nurse educator might seem high, particu-
larly when multiplied by the 1 million patients with this
problem. However, these costs need to be compared with
the expense associated with treating the ulcers that develop
as a consequence of no preventive measures and the disabil-
ity incurred by patients in whom ulcers develop. Weighing
these multiple variables and the short-term and long-term
costs, we found that it would be cost saving for Medicare
and other insurers to reimburse for a program of prophy-
laxis for patients with a history of venous stasis ulceration. If
only the costs to the insurer are considered (ie, the costs of
medical treatment), a program that includes compression
stockings and education saves $6326 during the lifetime of
each patient. Thus, even from the isolated view of the
insurer, it is economically advantageous to reimburse for a
program of prophylaxis. In sensitivity analysis, the cost of
compression therapy needed to be doubled or multiplied
by six times before this strategy was no longer cost saving or
cost-effective, respectively. Hence, other even more expen-
sive modes of compression therapy could be used as cost-
effective alternatives in patients who have difficulty apply-
ing compression stockings.
The cost related to days absent from work for patients
undergoing treatment for venous stasis ulceration was not
included in our base-case analysis. Although the revenue
lost from days away from work has little direct impact on
insurers, particularly non-Medicare insurers, loss of work
revenue is an issue that is important at a societal level. Thus,
we considered this factor in sensitivity analyses. With this
analysis, several assumptions were necessary for which there
are limited available data. We conservatively assumed that
50% of the 55-year-old patients would be actively em-
ployed. Moreover, we assumed that patients would be
unable to work for the entire duration of their treatment.
Although the intent of ambulatory compression stockings
or boots is for a patient to remain active during the course
of treatment, in our experience, it is only the occasional and
motivated patient who returns to work.7 As might be
anticipated, we found that including these indirect costs in
our analysis rendered a strategy of CS and Ed overwhelm-
ingly cost saving.
The higher the cost of treatment, the more critical it is
to prevent the development of venous ulceration. In deter-
mining this cost for the base-case analysis, we identified the
resources and expenses associated with one approach to
care. All patients were treated with Unna’s paste boot.19
These boots were changed weekly by a nurse with doctor
supervision. Numerous possible treatment regimes are
available for patients with stasis ulceration. A variety of
compression boots and dressings can be changed by nurs-
ing staff in clinic or in a patient’s home by visiting nurses.29
Because each of these treatment strategies might be associ-
ated with either a higher or lower cost relative to what we
used in our base-case analysis, we performed sensitivity
analyses with the cost of ulcer treatment as the variable. We
found that a treatment program that included compression
stockings and nursing education remained cost-effective
even if amputation and all costs of treatment for venous
stasis ulceration were eliminated. Moreover, recent studies
suggest that the actual treatment cost for venous stasis
ulceration may be higher than we derived for our base-case
analysis. Marston et al21 found an average cost of $2198 for
10 weeks of outpatient treatment (our base-case was
$1330, excluding hospitalizations). Olin et al5 reported a
total medical cost of $9685 per ulcer treated at the Cleve-
land Clinic Foundation.
Aside from cost containment, a prophylactic program
that reduces the frequency of ulcer recurrence also provides
improvement in quality of life. In our base-case analysis, we
applied to patients in whom venous stasis ulceration devel-
oped a quality-adjustment factor of 0.80 during the period
of treatment. Paraphrased, we assumed that patients with
an ulcer achieved only 80% of their usual state of health
during the period of treatment. There are substantial data
to support the contention that quality of life in these
patients is markedly impared.7,9,10 Patients cannot perform
their usual activities and are much less functional. A weekly
visit to the physician is necessary. In sensitivity analysis, we
found that reduced quality of life during ulcer treatment
was the primary factor that determined the overall quality-
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adjusted life expectancy, with cellulitis and amputation
playing a minor role. Although we believe strongly that the
quality of life of patients with ulceration is markedly re-
duced, if we eliminated this factor from our analysis, com-
pression stockings and patient education still remained cost
saving.
As described in our source studies,11,13,20,21 amputa-
tion as a consequence of venous stasis ulceration occurs in
the occasional patient, typically when venous insufficiency
is combined with arterial insufficiency. These patients com-
pose a unique subset and behave differently than the overall
cohort with just venous insufficiency. To eliminate such
patients from consideration, we performed sensitivity anal-
ysis excluding amputation and found that the prophylactic
strategy remained cost saving.
In our model, we presume that if patients are compli-
ant, the subsequent incidence rate of ulceration will mark-
edly diminish.12,13 Mayberry et al13 found a mean time to
recurrence of 61.7 months in patients who were compliant
with compression therapy versus 15.5 months in patients
who were not. Erickson et al11 similarly found a substantial
difference in recurrence between pateints who were com-
pliant and noncompliant (41% versus 71%, respectively, at 2
years). We also have made the presumption that if patients
are supplied stockings and proper education, there will be
100% compliance. Socioeconomic factors do play a major
role in a patient’s decision to purchase and use compression
stockings. For a treatment, which with the best of circum-
stances is fraught with lack of compliance, adding economic
disincentives will almost certainly lead to failure. In a study
by Samson and Showalter,12 78% of patients reported ex-
pense as reason for their noncompliance with compression
stockings. Various groups have established programs that
include education and frequent monitoring of patients with
chronic venous insufficiency. Erickson et al11 describe a
strategy in which a nurse clinician initiates a comprehensive
program of education, including basic pathophysiology,
signs and symptoms of venous insufficiency, and the impor-
tance of compression therapy. Patient comprehension is
evaluated at the end of these sessions, and additional teach-
ing is provided for those patients whose knowledge is
deficient. We realize, however, that with the best of educa-
tional programs and full reimbursement for compression
stockings, compliance will never be 100%. We also realize
that with no education or reimbursement for compression
stockings some patients still will be compliant, particularly
those patients in the higher socioeconomic levels. There-
fore, in sensitivity analyses, we evaluated the effect of a
reduction in compliance in the CS and Ed group on the
cost effectiveness of this strategy. We found that compli-
ance could drop from a base-case estimate of 100% down to
the minimal value of 16% before the prophylactic strategy
was no longer cost effective.
In summary, our analysis shows that it is cost saving to
provide compression stockings and education for patients
with a history of venous stasis ulceration. This finding is
driven by the profound difference in the rate of ulcer
recurrence in patients who are compliant with compression
therapy, the high cost of ulcer treatment, and the diminu-
tion in quality of life associated with venous stasis ulcer-
ation. Evaluation of the effect of less favorable assumptions
in sensitivity analysis shows a wide margin of confidence to
support our conclusion. Medicare and other insurers
should change their current practice and allow the costs of
prophylactic treatment to be reimbursed. This policy would
not only diminish the severe disability experienced by pa-
tients with recurrent venous ulceration but would also be
economically advantageous.
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